Table 2 Perioperative data and results
Perioperative data and results | Total patients (N = 90) |
|---|---|
Duration of surgery, min | 87 (58, 170) |
Duration of anesthesia, min | 121 (79, 215) |
Time from last NMBA dose administration to the end of anesthesia in patients who received > 1 dose, min | 167 (115, 185) |
Time from end of anesthesia to arrival in the RR, min | 6 (5, 8) |
Inhalational anesthesia | 51 (57) |
Target-controlled infusion anesthesia | 39 (43) |
Total dosage of sufentanil, mcg | 15 (10, 20) |
Total dosage of fentanyl, mcg | 200 (100, 200) |
Use of remifentanil | 52 (58) |
Neuromuscular blocking agent: | |
Rocuronium | 90 (100) |
Total dosage of rocuronium, mg kg−1 | 0.50 (0.20)x\x\ |
Received ≥ 1 dose of rocuronium | 5 (5) |
Reversal agent use: | |
Sugammadex | 11 (12) |
Total dose of sugammadex, mg | 200 (200, 300) |
Number of anesthesia monitoring charts that reported intraoperative neuromuscular monitoring | 41 (45) |
Number of anesthesia monitoring charts that reported basal TOFR at induction of anesthesia | 3 (3) |
Number of anesthesia monitoring charts that reported TOFR at extubation | 24 (27) |
Incidence of TOFR ≤ 0.9 at arrival in the RR | 5 (5) |
Patients with TOFR ≤ 0.9 requiring O2 supplementation during recovery room stay | 2 (2) |
Monitoring time in the RR, min | 60 (45, 75) |
Hospital length of stay, days | 2 (1, 3) |